intestinal tract (10) . Currently, a SMI for patients with pituitary disease and their partners addressing the psychosocial consequences and management of these consequences, of the disease is lacking.
Considering the patient and partner reported need for psychosocial care in pituitary disease, and the current lack of a SMI addressing psychological and social issues in these patients and their partners, the aim of the present study was to evaluate the effects of such a SMI in a randomized controlled trial in a large cohort of patients with pituitary disease and their partners.
ParTIcIPanTs and MeTHods design
This multicentre two-arm randomized controlled trial was initiated by researchers at the department of Medicine of the Leiden University Medical Centre (LUMC). Patients were randomized for the SMI or the control group; 1:1 randomization was performed by the first author (CDA). Partners of patients who agreed to participate (n=63) were allocated to the same condition as their ill partner.
For ethical reasons, patients and partners who were randomized to the control group were also offered the SMI after the last measurement. The medical ethical committee of the LUMC approved the study, and written informed consent was obtained from all participants.
Participants (figure 1)
The recruitment was coordinated by the out-patient departments of Medicine of the LUMC and the Radboud University Medical Centre (Radboudumc). Exclusion criteria were: <18 or >75 years of age; since older patients might have more comorbidity, current psychological treatment, current intensive medical treatment (e.g. radiotherapy, recovery from surgery) and psychiatric illness. A total number of 931 patients (and their partner when applicable) were informed about the study and were invited to participate (i.e. 462 from the LUMC; 469 from the Radboudumc). Reasons for not participating in the study were not speaking Dutch, not feeling comfortable talking in a group, too time consuming, burden too large (physically and/or mentally), not able to come due to other obligations (e.g. work, staying abroad, pregnancy, surgery), long travel distance, not perceiving problems, and no need for support (anymore), because patients already receive psychological counseling or previously received it, or learned to cope with their illness by themselves. One-hundred-and-eight patients (LUMC) and 80 patients (Radboudumc) agreed to participate. From the initial 188 incorporated patients, fourteen patients (7%) did not fill out the questionnaires. Therefore, a total number of 174 patients were included.
development of the sMI
The SMI was based on the standardized Patient (and Partner) Education Programme initially developed for Parkinson's disease (PEPP), and evaluated in seven European countries (11;12) including the Netherlands (13) (14) (15) , and is currently operational in patient care. The programme was then adapted for Huntington's disease (PEP-HD) (16) and was further developed and clinically tested in patients with chronic disease with psychiatric co-morbidity (17) .
Since the self-management techniques seemed to be generally applicable, the programme has recently been developed for patients with chronic disease in general (PPEP4ALL) (18) .
PPEP4ALL addresses psychological and social issues related to all chronic disease and uses techniques from cognitive behavioural therapy such as cognitive restructuring, systematic relaxation training, situational behavioural analyses, and training in social skills.
In order to assess whether PEPP was also suitable for patients with pituitary disease, focus group conversations in patients with pituitary disease were performed (3). The focus group guided us in laying the priorities and preferred options (e.g. fatigue, cognitive complaints, and problems with sexuality) within the PPEP4ALL. Based on these results we hypothesized PEPP/ PPEP4ALL ( Figure 2 ) would also be of relevance for patients with pituitary disease and their partners (when applicable). Then, we pilot tested it in 28 patients and 6 partners. Patients and partners reacted positively to the programme. Therefore, we decided to evaluate PPEP4ALL with the preferred options fatigue, cognitive complaints, and problems with sexuality. It was not necessary to drop any of the other components of PPEP4ALL and considering the patient group we named it the 'Patient and Partner Education Programme for Pituitary disease (PPEP-Pituitary)' . 
PPeP-Pituitary
PPEP-Pituitary includes self-management components of potential relevance for pituitary disease, i.e. fatigue management, stress management, dealing with anxiety and depression, and communication training (Supplement 1). The programme consisted of eight weekly sessions of 90 minutes moderated by psychologists and medical social workers. Patients and partners participated separately and from their own perspective, in groups of 5-7 participants at the LUMC or at the Radboudumc. The same one or two trainers guided each group for 8 weeks (CDA, SM, RM, NF, MP-D, RG, JL, MS, MV). All trainers were trained in/experienced with the PPEP/PPEP4ALL, and followed a one-day training to get familiar with the disease-specific focus on pituitary disease.
Procedure
All included participants were asked to fill-out questionnaires prior to the programme (T0).
Next, participants in PPEP-Pituitary followed the 8-week SMI, while the participants in the control group were invited for a single (optional) information meeting in week 4 or 5. For the formation of the patient groups, groups were stratified by disease in 3 groups i.e. 1) Cushing's disease (CD), 2) acromegaly or 3) prolactinoma/non-functioning pituitary adenoma (NFA)/ FSH-adenoma/craniopharyngeoma/hypopituitarism due to other causes. Partners in PPEP- Pituitary were not stratified by pituitary disease of their partner. Participants were asked to fill-out the questionnaires again after the 8-week intervention (T1) and 6 months later (T2).
Demographic characteristics (i.e. age, gender, marital status, education) and medication use were assessed by a self-report. Clinical characteristics of patients (e.g. type of pituitary disease, duration of follow-up) were derived from medical records.
Measures
For an overview of the used measures see Table 1 .
Based on the preference of participants, questionnaires were sent by email (online survey) or by regular mail, to increase the response rate. Hundred-nine patients and 53 partners completed the questionnaires online, and 65 patients and 10 partners by postal survey.
Previous research demonstrated that paper-and-pencil and online surveys do not lead to different results (19) . Partners completed the same questionnaires except the LBNQ-Pituitary, the EQ-5D, the IPA, and the disease-specific QoL questionnaires (i.e. AcroQoL, CushingQoL).
In addition, patients and partners in the PPEP-Pituitary group were asked to fill-out an evaluation form about PPEP-Pituitary (Supplement 2).
statistical analyses
Data were analyzed using PASW Statistics version 20.0.0 (SPSS Inc., Chicago, IL). To check the normality of data, the Kolmogorov-Smirnov test was used. Demographic characteristics and the baseline scores (Supplement 3) were compared using independent sample t-test and Chi-square test when data were normally distributed and by using Mann-Whitney U test and Fisher's exact when data were not normally distributed. To compare pre-and post-session mood ratings paired sample t-tests were used. A linear mixed model with random participant effect, and fixed time and group effects, as well as group by time interactions measured the effects of the programme. The linear mixed model enables accommodating missing data points (20) , and corrects for potential baseline differences. The effects of the programme were evaluated following intention to treat (ITT) principles, including all participants. Although ITT analysis is the golden standard for analyzing an RCT, it is also considered conservative (21) since not all participants in PPEP-Pituitary attended all sessions. Therefore, the post-hoc analyses comprised the clinical sample analyses including only the patients that attended at least six sessions, since this is the minimum amount of sessions to consider that someone completed PPEP-Pituitary, and since this situation will be more similar to the clinical situation. This analysis was performed using the same linear mixed model. The data from the evaluation were analyzed descriptively. Due to the explorative nature of this study, the level of significance was set at P<0.05. However, to take into account the effect of multiple testing, a Bonferroni correction was applied and a level of significance of P<.005 was also used. 
Mood changes after each PPeP-Pituitary session (Table 3)
Patient reported mood improved significantly after each session (all P<.001), except for session 1. Partners' mood improved only after sessions 6, 7, and 8 (all P≤.030).
effects of intervention: Intention to treat analysis (Table 4)

Self-efficacy
For patients a significant interaction was found for self-efficacy (GSE) (P=.020), with PPEP-Pituitary reporting more self-efficacy compared to controls (difference 1.35, P=.016) (T1 vs.
T0), which persisted up to the 6 month follow-up (difference 1.74, P=.033) (T2 vs T0). No significant difference in self-efficacy was observed in partners.
Bother and Needs for support
An interaction was found for being bothered by mood problems (LBNQ-Pituitary) (P=.002), with PPEP-Pituitary, reporting to be less bothered by mood problems compared to controls (difference -6.27, P=.010) (T1 vs. T0). At T2 relative to T1, PPEP-Pituitary reported more bother by mood problems compared to controls (difference 8.71, P=.001), but this increase at T2 was not significantly different from baseline (difference 2.44, P=.346). Furthermore, an interaction was observed on the Total score of the Bothered by items of the LBNQ-Pituitary (P=.028),
with PPEP-Pituitary reporting more overall bother (total score) at T2 relative to T1 compared to controls (difference 4.58, P=.008), but this increase at T2 was also not significantly different from baseline (difference 2.20, P=.219). 
Illness perceptions
No significant differences in illness perceptions (B-IPQ) were observed for patients over time.
For partners an interaction was found for perceived treatment control (P=.025), with PPEP-Pituitary perceiving more treatment control compared to controls (difference 3.12, P=.008) (T2 vs. T1), but this increase at T2 was not significant from baseline (difference 1.43, P=.230)
Coping No significant differences in coping styles (UCL) were found for patients and partners over time.
Participation and autonomy
No significant differences in participation and autonomy (IPA) were found for patients over time.
Quality of life
For patients no significant differences were found for QoL (i.e. EQ-5D, SF-36, MFI-20, HADS, CushingQoL, AcroQoL).
For partners an interaction was found for vitality ( Finally, an interaction was found for the HADS total score (P=.005), with PPEP-Pituitary re- porting a lower total HADS score at T2 relative to T0 (difference -6.51, P=.002), as well as at T2
relative to T1 (difference -4.54, P=.034) compared to controls. This seems to indicate that partners needed time to implement the newly learned skills in their daily lives. It could also be that aspects of QoL improved in partners as a result of the improvement in self-efficacy in their ill partners.
Post-hoc analysis: clinical sample
Patient and partner evaluation
In the present study we did not observe any effects in patients on QoL, illness perceptions, coping, and autonomy and participation in different life domains. It should, however, be noted there was a relatively long duration since diagnosis (i.e. PPEP-Pituitary: 12 years, control group: 13 years). It is conceivable that during this long period of living with the disease, patients and partners adapted to the consequences of the disease and/or already had received appropriate support, which may have limited the beneficial effects of our programme in improving psychosocial aspects. It should also be realized that although some aspects did From the notes written on the evaluation forms it became apparent that patients would have liked more (practical, medical) information about their disease (i.e. bodily changes due to disease, medication, side-effects). Therefore, we are considering the invitation of an endocrine nurse to the first session to provide (practical) information about the disease. For future implementation of PPEP-Pituitary, it is very difficult to form separate groups per disease (i.e. CD, acromegaly, NFA/PRL), considering the low incidence of pituitary adenomas. Therefore, we postulate that groups can be formed with patients with different pituitary diseases. This seems to be suitable considering the overlapping symptoms (i.e. hypopituitarism, fatigue), but on the other hand it can be imagined that for a patient it can be helpful to have at least one other person in the group with the same disease. Future implementation of PPEP-Pituitary groups of patients with different pituitary diseases can be formed, but with taking into account the distribution of diseases per group. Furthermore, a question that needs to be further clarified in future research is determining the best moment to offer PPEP-Pituitary during the disease process. We believe that directly after biomedical treatment is not the right moment, because patients need their time and energy to recover from treatment, but also because patients will not have a clear idea about the psychosocial consequences of the disease making it difficult to work on during PPEP-Pituitary. On the other hand, when the programme is offered years after biomedical treatment, patient may have learned to cope with the consequences and/or they had to search for psychological care by themselves. Therefore, we postulated that the ideal moment to offer the programme will be between 6-12 months after biochemical remission. It is speculated that offering the programme at that time might lead to less healthcare consumption. Therefore, for future research it would be interesting to assess the effects of PPEP-Pituitary in a clinical setting that also includes patients that have recently obtained a stable medical situation.
In 2. The exchange of experiences and ideas within the group was helpful.
3. The information presented in the programme often confused me.
4. I would have liked even more information to be presented.
5. Too much theoretical information was given during the programme.
6. Much of the information was new to me.
7. My understanding of the pituitary disease and the problems associated with the pituitary disease has improved.
8. I believe that I can now deal better with the problems related to the pituitary disease.
9. Too little practical information was given during the programme. Total score 10.4 (7.0) 11.3 (6.9) 7.3 (6.2) 11.2 (8.7) 
IPQ-brief
